Literature DB >> 24956694

Continuous spinal anaesthesia for caesarean section in a parturient with peripartum cardiomyopathy.

S Fyneface-Ogan, J D Ojule.   

Abstract

Peripartum cardiomyopathy is a potentially fatal form of heart failure associated with pregnancy. A 27-year-old Nigerian woman, gravida 1, para 0, presented at 31 weeks' gestation with no previous history of hypertension heart disease, but morbidly obese (body mass index of 42 kg/m2), with uncontrolled and hypertension, severe pulmonary oedema who required an urgent Caesarean section is presented. The patient was admitted into the hospital's ICU for stabilisation. She was placed on oxygen by non-rebreathing face mask while receiving intravenous labetalol and frusemide. Following a worsening clinical state, an urgent Caesarean section was conducted under continuous spinal anaesthesia using 7.5 mg intrathecal 0.5% isobaric bupivacaine and was delivered of a 1.8 Kg live female baby with good Apgar scores. At the end of the surgery, mother and baby were transferred to the ICU and SCBU respectively. After a 7-day intensive treatment she was discharged. Since then she remained symptom-free and her baby was doing well during the period of admission and discharge. This case report illustrated the recognition of peripartum cardiomyopathy and the use of a more haemodynamic stable anaesthetic technique. It also described the need for collaboration of multiple medical specialists before, during delivery and after delivery to provide the best possible outcome for both mother and infant.

Entities:  

Mesh:

Year:  2014        PMID: 24956694

Source DB:  PubMed          Journal:  Niger J Med        ISSN: 1115-2613


  1 in total

1.  Perioperative management of emergent cesarean section in a patient with peripartum cardiomyopathy and orthopnea: a case report.

Authors:  Yuko Kawamoto; Tasuku Nishihara; Jun Aono; Hideyuki Nandate; Taisuke Hamada; Toshiaki Yasuoka; Takashi Matsumoto; Osamu Yamaguchi; Takashi Sugiyama; Toshihiro Yorozuya
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.